CorMedix Inc. Reports Material Agreements, Acquisitions, and Officer Changes

TL;DR

CorMedix filed an 8-K detailing new deals, asset changes, equity sales, and exec shuffles. Big moves happening.

AI Summary

CorMedix Inc. filed an 8-K on August 28, 2025, reporting several key events. These include entering into a material definitive agreement, the completion of an acquisition or disposition of assets, and unregistered sales of equity securities. The filing also notes the departure of directors or officers, the election of new directors, and the appointment of new officers, along with compensatory arrangements. Additionally, it contains a Regulation FD disclosure and financial statements/exhibits.

Why It Matters

This 8-K filing indicates significant corporate actions for CorMedix Inc., including potential strategic shifts through acquisitions/dispositions and changes in leadership, which could impact its future operations and stock performance.

Risk Assessment

Risk Level: medium — The filing involves multiple significant corporate events including definitive agreements, acquisitions/dispositions, and equity sales, which inherently carry a medium level of risk due to their potential impact on the company's financial health and strategic direction.

Key Players & Entities

• CorMedix Inc. (company) — Registrant
• August 28, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 001-34473 (company_id) — Commission File Number

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share CRMD Nasdaq Glo
• $20 million — FDA-approved labeling includes candida, $20 million; (ii) if the FDA-approved labeling i
• $2.5 million — approved labeling includes aspergillus, $2.5 million; and (iii) if the FDA-approved label
• $260 million — enting Melinta Members) an aggregate of $260 million in cash (subject to adjustment for the
• $40 million — senting Melinta Members an aggregate of $40 million worth of common shares, par value $0.00
• $150 million — e Company's existing cash on hand and a $150 million convertible notes offering. The forego
• $488,000 — led to receive an annual base salary of $488,000, $500,000, and $423,833, respectively,
• $500,000 — eive an annual base salary of $488,000, $500,000, and $423,833, respectively, and each w
• $423,833 — base salary of $488,000, $500,000, and $423,833, respectively, and each will be eligibl
• $1,000,000 — shares of Common Stock with a value of $1,000,000 (determined based on the closing price

Filing Documents

• ea0255371-8k_cormedix.htm (8-K) — 52KB
• ea025537101ex10-1_cormedix.htm (EX-10.1) — 171KB
• ea025537101ex10-2_cormedix.htm (EX-10.2) — 142KB
• ea025537101ex10-3_cormedix.htm (EX-10.3) — 216KB
• ea025537101ex10-4_cormedix.htm (EX-10.4) — 204KB
• ea025537101ex10-5_cormedix.htm (EX-10.5) — 188KB
• ea025537101ex99-1_cormedix.htm (EX-99.1) — 35KB
• ex99-1_001.jpg (GRAPHIC) — 15KB
• 0001213900-25-082956.txt ( ) — 1430KB
• crmd-20250828.xsd (EX-101.SCH) — 3KB
• crmd-20250828_lab.xml (EX-101.LAB) — 33KB
• crmd-20250828_pre.xml (EX-101.PRE) — 22KB
• ea0255371-8k_cormedix_htm.xml (XML) — 4KB

02. Departure of Directors or Certain

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The Company announced today that Susan Blum, Elizabeth Hurlburt and Matthew David (each, an "Executive")have been appointed to serve as the Company's Chief Financial Officer, Chief Operating Officer and Chief Business Officer, respectively, each effective as of the Closing Date. In their previous roles, Ms. Blum served as the Chief Financial Officer of Melinta, Ms. Hurlburt as EVP, Chief Clinical Strategy and Operations Officer of the Company, and Dr. David as Chief Financial Officer of the Company. Effective as of the Closing Date, Dr. David ceased to serve, and Ms. Blum commenced serving, as the Company's principal financial officer. - 2 - Ms. Blum was previously the Chief Financial Officer of Melinta. Ms. Blum joined Melinta in 2016 as the company's Controller and then served as Vice President of Finance & Chief Accounting Officer prior to being appointed to the Chief Financial Officer position in 2021. Prior to joining Melinta, Ms. Blum served as Corporate Controller at Textura Corporation from 2013 to 2016, supporting the company's IPO and transformation into a publicly-traded organization. Ms. Blum also served in leadership roles at Orbitz Worldwide, Inc. (NYSE: OWW) from 2011 to 2013 and at Facet Biotech Corporation and PDL BioPharma, Inc. (Nasdaq: PDLI) from 2004 to 2010, where she was responsible for such functions as external reporting and related compliance, technical accounting and internal controls over financial reporting. Ms. Blum has served as a director of BiomX Inc. since April 2024. Ms. Blum began her career in public accounting at Ernst & Young, where she spent nearly seven years working with a diverse client base ranging from large, public international engagements to development-stage enterprises. Ms. Blum is a Certified Public Accountant, currently serves as a member of the BioNJ Cybe

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CorMedix Inc. Date: September 2, 2025 By: /s/ Joseph Todisco Joseph Todisco Chief Executive Officer - 5 -

View Full Filing

View this 8-K filing on SEC EDGAR